Site icon pharmaceutical daily

Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

TAZVERIK™ (tazemetostat) Commercial Launch Underway for Epithelioid Sarcoma

TAZVERIK sNDA for Follicular Lymphoma Accepted for Filing by FDA with Priority Review; PDUFA Target Action Date of June 18, 2020

Expanding Future TAZVERIK Value through Clinical Development into New Combinations and Indications

Conference Call to be Held Today, Feb. 24 at 8:30 a.m. ET

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2019 financial results.

“We began 2020 with the most meaningful milestone for the company to date – the accelerated approval of TAZVERIK, making it the first and only commercially available EZH2 inhibitor and the only approved product specifically indicated for epithelioid sarcoma patients. We executed a strong start to our commercial launch, in which we made TAZVERIK available to patients within one week of approval,” said Robert Bazemore, president and chief executive officer of Epizyme. “Following the acceptance of our sNDA filing for TAZVERIK for follicular lymphoma, we are preparing to quickly address the more prevalent FL patient population, if approved. In parallel, we are continuing our in-house and clinical collaboration efforts to demonstrate the full potential of tazemetostat for a range of cancer indications, with 12 trials underway and four more planned for initiation this year, making for a robust development expansion program.”

Recent Progress

2020 Company Priorities

Epizyme has outlined the following key milestones for 2020:

Epithelioid Sarcoma

Follicular Lymphoma

Additional Indications

Epizyme plans to explore the utility of tazemetostat in additional indications, as a monotherapy and in combinations, through in-house efforts, investigator-sponsored studies and clinical collaborations. Based on scientific hypotheses and unmet need, these areas include:

Preclinical Pipeline

Financial Guidance

Based on its current operating plans, Epizyme expects its current cash runway to extend into at least 2022. Additionally, the company expects its GAAP operating expenses for 2020 to be between $300 and $330 million inclusive of the milestones due to Eisai for the FDA approval of TAVERIK for epithelioid sarcoma and for follicular lymphoma, if approved.

Fourth Quarter and Full Year 2019 Financial Results

Conference Call Information

Epizyme will host a conference call today, Feb. 24, at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 9045277. A live webcast and slides will be available in the investor section of the company’s website at www.epizyme.com, and will be archived for 60 days following the call and presentation.

About TAZVERIK

TAZVERIK™ (tazemetostat) is the first EZH2 inhibitor approved by the U.S. Food and Drug Administration (FDA). TAZVERIK™ is an enhancer of zeste homolog 2 (EZH2) methyltransferase inhibitor indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For more information, visit TAZVERIK.com.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK™ (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication is contingent upon verification and description of clinical benefit in an ongoing confirmatory trial. The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether tazemetostat will receive marketing approval for epithelioid sarcoma in other jurisdictions, full approval in the United States or approval in any other indication; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials, such as the ongoing confirmatory trial; whether results from clinical studies will warrant meetings with regulatory authorities, submissions for regulatory approval or review by governmental authorities under the accelerated approval process; expectations for regulatory approvals, including accelerated approval, to conduct trials or to market products; whether the company’s cash resources will be sufficient to fund the company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial success of tazemetostat or the company’s therapeutic candidates; and other factors discussed in the “Risk Factors” section of the company’s most recent Form 10-Q filed with the SEC and in the company’s other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

TAZVERIK™ is a trademark of Epizyme, Inc.

 

EPIZYME, INC.

CONSOLIDATED BALANCE SHEET DATA (UNAUDITED)

(Amounts in thousands )

 
 

December 31,

2019

December 31,

2018

Consolidated Balance Sheet Data:

Cash and cash equivalents

 $

       139,482

 $

       86,671

Marketable securities

 

          241,605

 

        153,633

Total assets

 

          424,589

 

        275,501

Total current liabilities

 

           34,386

 

          37,833

Deferred revenue

 

             3,806

 

          17,106

Long-term debt, net of debt discount

 

           23,309

                —

Liability related to sale of future royalties

 

           12,793

                —

Total stockholders’ equity

          $

331,137

     $

233,009

 

EPIZYME, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS  (UNAUDITED)

 (Amounts in thousands except per share data)

Three Months Ended

December 31,

Year Ended

December 31,

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Collaboration revenue

 $

      4,294

 

 $

      9,700

 

 $

        23,800

 

 $

        21,700

 

Operating expenses:

Research and development

 

       38,257

 

 

       21,838

 

 

         132,639

 

 

         105,833

 

General and administrative

 

       23,530

 

 

       12,170

 

 

           68,303

 

 

           43,972

 

Total operating expenses

 

       61,787

 

 

       34,008

 

 

         200,942

 

 

         149,805

 

Operating loss

 

      (57,493

)

 

      (24,308

)

 

        (177,142

)

 

        (128,105

)

Other income, net:

Interest income, net

 

  1,320

 

 

         1,420

 

 

  7,110

 

 

             4,557

 

Other income (expense), net

 

  21

 

             —

 

  (13

)

 

                (25

)

Non-cash interest expense related to sale of future royalties

 

  (192

)

             —

 

  (192

)

                 —

Other income, net

 

  1,149

 

 

         1,420

 

 

  6,905

 

 

             4,532

 

Loss before income taxes

 

  (56,344

)

 

  (22,888

)

 

  (170,237

)

 

  (123,573

)

Income tax (provision)

 

  (58

)

 

            (57

)

 

  (58

)

 

                (57

)

Net loss

 $

  (56,402

)

 $

  (22,945

)

 $

     (170,295

)

 $

     (123,630

)

Other comprehensive income (loss):

Unrealized (loss) gain on available-for-sale securities

 

  (130

)

 

            (31

)

 

  73

 

 

                  (5

)

Comprehensive loss

 $

  (56,532

)

 $

  (22,976

)

 $

     (170,222

)

 $

     (123,635

)

 
 

Reconciliation of net loss to net loss attributable to common stockholders:

Net loss

 $

  (56,402

)

 $

  (22,945

)

 $

     (170,295

)

 $

     (123,630

)

Accretion of convertible preferred stock

             —

             —

 

            (2,940

)

                 —

Net loss attributable to common stockholders

 $

  (56,402

)

 $

  (22,945

)

 $

     (173,235

)

 $

     (123,630

)

Net loss per share attributable to common stockholders – basic and diluted

 $

      (0.59

)

 $

      (0.29

)

 $

           (1.93

)

 $

           (1.72

)

Weighted-average common shares outstanding used in net loss per share attributable to

   common stockholders – basic and diluted

 

       95,074

 

 

       78,962

 

 

           89,891

 

 

           71,864

 

 

Contacts

Media:
Erin Graves, Epizyme, Inc.

media@epizyme.com
(617) 500-0615

Investors:
Alicia Davis, THRUST Strategic Communications

alicia@thrustsc.com
(910) 620-3302

Exit mobile version